It is, therefore, reasonable to infer that MMP2 could be a therapeutic target for the treatment of osteoporosis.SORBS1 refers to the insulin signaling molecules expressed in fat and skeletal muscle that is involved in the regulation of signaling pathways within the cytoskeleton [70, 71]. The gene discussed is MMP2; the disease is osteoporosis.